Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Drug company (FDA labeler)

HF Acquisition Co. LLC, DBA Health First

NDC labeler code: 51662

What is a labeler?

The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.

Official FDA data only

Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.

Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.

At a glance

7Products (NDC)

Prescription medicines

FDA applications for these products

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
ApprovedApplicationMedicineSponsor
March 23, 2009ANDA078527 Flumazenil
FLUMAZENIL
Hikma Farmaceutica
April 25, 2000ANDA075151 Magnesium sulfate heptahydrate
MAGNESIUM SULFATE
Hospira
January 7, 1987ANDA070256 Naloxone hydrochloride
NALOXONE HYDROCHLORIDE
Hospira
June 3, 1986NDA019445 Dextrose monohydrate
DEXTROSE 25%, DEXTROSE 50%
Hospira
May 19, 1981NDA018132 Dopamine hydrochloride
DOPAMINE HYDROCHLORIDE
Hospira
November 27, 1972ANDA080817 Diphenhydramine
DIPHENHYDRAMINE HYDROCHLORIDE
West-Ward Pharms Int
October 31, 1972ANDA083158 Lidocaine
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%
Hospira

The sponsor is the company that holds the FDA application; it can differ from the labeler.

Recall timeline

2023

  1. June 6, 2023 · Class III · Terminated · D-0870-2023 · Glycopyrrolate

    Labeling: Label Mix-up

    GLYCOPYRROLATE INJECTION, USP 0.2MG/ML, 1mL VIAL, manufactured by HF Acquisition Co. LLC, Mukilteo, WA 98275, NDC 51662-1487-3

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026

FDA Enforcement Report search → · Report an error →